Fig. 6: EMT induction and RBM15 upregulation as precursors to osimertinib resistance development. | Oncogene

Fig. 6: EMT induction and RBM15 upregulation as precursors to osimertinib resistance development.

From: RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1

Fig. 6

A H1975 cells were exposed to 1 μm osimertinib and cultured for 20 days to select H1975-DTP cells (top panel). H1975 and H1975-DTP cells were incubated with osimertinib for 48 h, cell viability was measured using the CCK-8 assay, and the IC50 was calculated (bottom panel). T test. B Western blot investigation of EGFR, ERK, and AKT protein levels and their phosphorylation. C Western blot assessment of RBM15 protein expression levels in H1975 and H1975-DTPCs. D, E Western blot and immunofluorescence assessment of EMT marker proteins in H1975 and H1975-DTP cells (scale bar: 50 μm). T test. F A model diagram demonstrating that RBM15 suppresses SPOCK1 mRNA expression through m6A modification, enhancing EMT-mediated osimertinib resistance in refractory tumors. This figure was created using the BioRender website (https://biorender.com). Error bars represent the means ± SDs. ***P < 0.001, ****P < 0.0001.

Back to article page